Mirum Pharmaceuticals Inc Revenue Growth Rates (MIRM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Mirum Pharmaceuticals Inc   (NASDAQ: MIRM)
 

MIRM's Revenue Growth by Quarter and Year

Mirum Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MIRM Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 176.24
1st Quarter March 159.88
FY 336.12

MIRMs Annual Revenue
Mirum Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 521.31 millions
Mirum Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 336.89 millions
Mirum Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 186.37 millions
Mirum Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 77.06 millions
Mirum Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 19.14 millions




MIRM Revenue second quarter 2026 Y/Y Growth Comment
Mirum Pharmaceuticals Inc reported Revenue improvement of 37.92% year on year in the second quarter 2026, to $ 176.24 millions, this is lower than Mirum Pharmaceuticals Inc 's recent average Revenue surge of 107.69%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 75 other companies have achieved higher Revenue growth. While Mirum Pharmaceuticals Inc ' s Revenue rise of 37.92% ranks overall at the positon no. 1223 in the second quarter 2026.


MIRM Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 49.81 % 42.93 % 149.19 %
3rd Quarter September - 47.17 % 89.36 % 154.15 %
2nd Quarter June 37.92 % 64.09 % 107.68 % 114.53 %
1st Quarter March 43.27 % 61.21 % 119.05 % 145.15 %
FY   - 54.74 % 80.75 % -

Financial Statements
Mirum Pharmaceuticals Inc 's second quarter 2026 Revenue $ 176.24 millions MIRM's Income Statement
Mirum Pharmaceuticals Inc 's second quarter 2025 Revenue $ 127.79 millions Quarterly MIRM's Income Statement


MIRM Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 11.97 % 9.99 % 45.72 %
3rd Quarter September - 4.08 % 16.05 % 27.28 %
2nd Quarter June 10.23 % 14.52 % 12.51 % 18.67 %
1st Quarter March 7.35 % 12.25 % -0.47 % 13.22 %
FY (Year on Year)   - 54.74 % 80.75 % -


Back to MIRM Growth rate Comparisons >> Back to MIRM Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #76
Healthcare Sector #219
Overall #1223

Revenue Y/Y Growth Statistics
High Average Low
200.62 % 107.69 % 44.02 %
(Jun 30 2023)   (Jun 30 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #76
Healthcare Sector #219
Overall #1223
Revenue Y/Y Growth Statistics
High Average Low
200.62 % 107.69 % 44.02 %
(Jun 30 2023)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Mirum Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
310.83 % 25.7 % -54.55 %
(Mar 31 2022)  


MIRM's II. Quarter Q/Q Revenue Comment
Mirum Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue rise of 10.23% quarter on quarter, to $ 176.24 millions.

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Mirum Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 802.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #123
Overall #802
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #123
Overall #802
Revenue Q/Q Growth Statistics
High Average Low
310.83 % 25.7 % -54.55 %
(Mar 31 2022)  


MIRM's II. Quarter Q/Q Revenue Comment
Mirum Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue rise of 10.23% quarter on quarter, to $ 176.24 millions.

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Mirum Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 802.


Mirum Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 618.07 $ 569.61 $ 521.31 $ 471.79 $ 429.16
Y / Y Revenue Growth (TTM) 44.02 % 50.19 % 54.74 % 53.66 % 62.33 %
Year on Year Revenue Growth Overall Ranking # 276 # 70 # 47 # 82 # 76
Seqeuential Revenue Change (TTM) 8.51 % 9.26 % 10.5 % 9.93 % 13.16 %
Seq. Revenue Growth (TTM) Overall Ranking # 1223 # 918 # 546 # 669 # 425


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Mirum Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 618 millions, company would post below average annual Revenue growth of 13.16% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Mirum Pharmaceuticals Inc 's Revenue growth from the 159.88% growth in Mar 31 2026.

In the Healthcare sector 73 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 70 to 276.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 76
Healthcare Sector # 74
Overall # 276

Revenue TTM Y/Y Growth Statistics
High Average Low
200.62 %
 107.69 %
44.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 76
Sector # 219
S&P 500 # 1223
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Mirum Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 618 millions, company would post below average annual Revenue growth of 44.02% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Mirum Pharmaceuticals Inc 's Revenue growth from the 159.88% growth in Mar 31 2026.

In the Healthcare sector 73 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 70 to 276.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 76
Healthcare Sector # 74
Overall # 276

Revenue TTM Y/Y Growth Statistics
High Average Low
200.62 %
107.69 %
44.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 76
Sector # 219
S&P 500 # 1223




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MIRM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions


About Mirum Pharmaceuticals Inc Revenue Growth Rates (MIRM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Mirum Pharmaceuticals Inc (CIK 1759425).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001759425-26-000045
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Mirum Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.